D. Boral Capital Reaffirms Buy Rating for GeoVax Labs (NASDAQ:GOVX)

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports. They currently have a $18.00 price objective on the stock.

Several other equities analysts have also recently issued reports on the company. Alliance Global Partners began coverage on GeoVax Labs in a research report on Monday, November 11th. They issued a “buy” rating and a $15.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of GeoVax Labs in a report on Friday, November 15th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $14.20.

GeoVax Labs Stock Performance

Shares of NASDAQ GOVX opened at $1.44 on Thursday. The firm’s 50 day moving average price is $2.00 and its 200-day moving average price is $2.64. GeoVax Labs has a 52-week low of $1.09 and a 52-week high of $11.18.

Institutional Investors Weigh In On GeoVax Labs

Hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC purchased a new position in shares of GeoVax Labs in the 4th quarter worth $104,000. Virtu Financial LLC bought a new position in GeoVax Labs in the third quarter valued at about $97,000. Geode Capital Management LLC boosted its position in GeoVax Labs by 59.0% in the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after purchasing an additional 33,440 shares during the last quarter. Finally, Northern Trust Corp bought a new stake in shares of GeoVax Labs during the 4th quarter valued at about $29,000. 6.09% of the stock is currently owned by hedge funds and other institutional investors.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.